Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Dermatology

  Free Subscription


Articles published in N Engl J Med

Retrieve available abstracts of 109 articles:
HTML format



Single Articles


    January 2023
  1. ROSMARIN D, Kornacki D, Ezzedine K
    Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo. Reply.
    N Engl J Med. 2023;388:284.
    PubMed    


  2. JANSSEN JC, Mulder EEAP, van der Veldt AAM
    Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo.
    N Engl J Med. 2023;388:283.
    PubMed    


  3. TANG B, Chang X
    Condylomata Lata.
    N Engl J Med. 2023;388:e3.
    PubMed    


  4. AGGARWAL R, Charles-Schoeman C, Schessl J
    Trial of Intravenous Immune Globulin in Dermatomyositis. Reply.
    N Engl J Med. 2023;388:94-95.
    PubMed    


  5. WERTH VP, Fiorentino DF, Vleugels RA
    Trial of Intravenous Immune Globulin in Dermatomyositis.
    N Engl J Med. 2023;388:94.
    PubMed    


    December 2022
  6. MAALOUF NS, Morand M
    Serpentine Supravenous Hyperpigmentation.
    N Engl J Med. 2022;387:e67.
    PubMed    


  7. PAYNE AS
    Topical Gene Therapy for Epidermolysis Bullosa.
    N Engl J Med. 2022;387:2281-2284.
    PubMed    


  8. SCHAFFER DV
    The Coming of Age of Topical Gene Therapy for Dystrophic Epidermolysis Bullosa.
    N Engl J Med. 2022;387:2279-2280.
    PubMed    


  9. GUIDE SV, Gonzalez ME, Bagci IS, Agostini B, et al
    Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa.
    N Engl J Med. 2022;387:2211-2219.
    PubMed     Abstract available


  10. VIEDMA-MARTINEZ M, Villegas Romero I
    Skin Necrosis after Transarterial Chemoembolization.
    N Engl J Med. 2022;387:2268.
    PubMed    


  11. CHARI A, Minnema MC, Berdeja JG, Oriol A, et al
    Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma.
    N Engl J Med. 2022;387:2232-2244.
    PubMed     Abstract available


  12. ROHAAN MW, Borch TH, van den Berg JH, Met O, et al
    Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.
    N Engl J Med. 2022;387:2113-2125.
    PubMed     Abstract available


  13. LANG DM
    Chronic Urticaria. Reply.
    N Engl J Med. 2022;387:2103.
    PubMed    


  14. ROLLA G
    Chronic Urticaria.
    N Engl J Med. 2022;387:2102-2103.
    PubMed    


  15. WEINBERGER M
    Chronic Urticaria.
    N Engl J Med. 2022;387:2102.
    PubMed    


  16. BONNIN AJ
    Chronic Urticaria.
    N Engl J Med. 2022;387:2101-2102.
    PubMed    


  17. DESCAMPS V
    Chronic Urticaria.
    N Engl J Med. 2022;387:2101.
    PubMed    


    November 2022
  18. ZHOU HY, Liu ZH
    Pyoderma Gangrenosum.
    N Engl J Med. 2022;387:e48.
    PubMed    


    October 2022
  19. COHEN EM, Sobrin L, Figueiro Longo MG, Pier DB, et al
    Case 33-2022: An 11-Year-Old Girl with Redness of the Eyes.
    N Engl J Med. 2022;387:1598-1607.
    PubMed    


  20. WERTH VP, Barbey C, Franchimont N
    Anti-BDCA2 Antibody for Cutaneous Lupus Erythematosus. Reply.
    N Engl J Med. 2022;387:1529.
    PubMed    


  21. PSARRAS A, Vital EM
    Anti-BDCA2 Antibody for Cutaneous Lupus Erythematosus.
    N Engl J Med. 2022;387:1528-1529.
    PubMed    


  22. EIDSMO L
    New Hope for Patients with Vitiligo.
    N Engl J Med. 2022;387:1515-1516.
    PubMed    


  23. DESAI AS, Dudzinski DM, Stib MT, Chen ST, et al
    Case 32-2022: A 76-Year-Old Man with Postoperative Cardiogenic Shock and Diffuse Rash.
    N Engl J Med. 2022;387:1502-1513.
    PubMed    


  24. LEE JB, Schwartz Z
    Tinea Nigra.
    N Engl J Med. 2022;387:1501.
    PubMed    


  25. ROSMARIN D, Passeron T, Pandya AG, Grimes P, et al
    Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo.
    N Engl J Med. 2022;387:1445-1455.
    PubMed     Abstract available


  26. CORTES J, Zhou X, Schmid P
    Pembrolizumab in Triple-Negative Breast Cancer. Reply.
    N Engl J Med. 2022;387:1436.
    PubMed    


  27. ALTUNDAG K
    Pembrolizumab in Triple-Negative Breast Cancer.
    N Engl J Med. 2022;387:1435-1436.
    PubMed    


  28. SUN R, Wei LJ
    Pembrolizumab in Triple-Negative Breast Cancer.
    N Engl J Med. 2022;387:1435.
    PubMed    


  29. REBELLO A, Joshi P
    Giant-Cell Arteritis.
    N Engl J Med. 2022;387:e36.
    PubMed    


  30. AMATO AA
    Intravenous Immune Globulin Therapy in Dermatomyositis.
    N Engl J Med. 2022;387:1320-1321.
    PubMed    


  31. KHAITAN BK, Ahuja R
    Erythema Ab Igne.
    N Engl J Med. 2022;387:e33.
    PubMed    


  32. AGGARWAL R, Charles-Schoeman C, Schessl J, Bata-Csorgo Z, et al
    Trial of Intravenous Immune Globulin in Dermatomyositis.
    N Engl J Med. 2022;387:1264-1278.
    PubMed     Abstract available


    September 2022
  33. MODI S, Gambhire D, Cameron D
    Trastuzumab Deruxtecan in HER2-Low Breast Cancer. Reply.
    N Engl J Med. 2022;387:1145-1146.
    PubMed    


  34. CARROLL HK, Higgins MJ, O'Reilly S
    Trastuzumab Deruxtecan in HER2-Low Breast Cancer.
    N Engl J Med. 2022;387:1144.
    PubMed    


  35. SCHNOG JB, Samson MJ, Duits AJ
    Trastuzumab Deruxtecan in HER2-Low Breast Cancer.
    N Engl J Med. 2022;387:1143-1144.
    PubMed    


  36. GROSS ND, Miller DM, Khushalani NI, Divi V, et al
    Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma.
    N Engl J Med. 2022 Sep 12. doi: 10.1056/NEJMoa2209813.
    PubMed     Abstract available


  37. FURIE RA, van Vollenhoven RF, Kalunian K, Navarra S, et al
    Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus.
    N Engl J Med. 2022;387:894-904.
    PubMed     Abstract available


  38. LANG DM
    Chronic Urticaria.
    N Engl J Med. 2022;387:824-831.
    PubMed    


    August 2022
  39. CHRISTIAN NT, Borges VF
    What Dobbs Means for Patients with Breast Cancer.
    N Engl J Med. 2022 Aug 27. doi: 10.1056/NEJMp2209249.
    PubMed    


  40. SOUMERAI JD
    Case 16-2022: A Man with Fevers, Night Sweats, and a Mediastinal Mass. Reply.
    N Engl J Med. 2022;387:763-764.
    PubMed    


  41. FAJGENBAUM DC
    Case 16-2022: A Man with Fevers, Night Sweats, and a Mediastinal Mass. Reply.
    N Engl J Med. 2022;387:763.
    PubMed    


  42. VAN RHEE F
    Case 16-2022: A Man with Fevers, Night Sweats, and a Mediastinal Mass.
    N Engl J Med. 2022;387:762-763.
    PubMed    


  43. ZOSHIMA T, Kawano M
    Tongue Telangiectasias in Systemic Sclerosis.
    N Engl J Med. 2022;387:737.
    PubMed    


  44. KAHN M, Fleece M
    Rice Bodies in Tenosynovitis Due to Psoriatic Arthritis.
    N Engl J Med. 2022;387:e14.
    PubMed    


  45. ZHANG W, Zhang ZL
    Lupus Pernio in Sarcoidosis.
    N Engl J Med. 2022;387:546.
    PubMed    


    July 2022
  46. WERTH VP, Furie RA, Romero-Diaz J, Navarra S, et al
    Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus.
    N Engl J Med. 2022;387:321-331.
    PubMed     Abstract available


  47. BOYCE M, Flower C
    Tripe Palms.
    N Engl J Med. 2022;387:355.
    PubMed    


  48. PIVOT X
    Pembrolizumab in the Treatment of Breast Cancer.
    N Engl J Med. 2022;387:273-274.
    PubMed    


  49. CORTES J, Rugo HS, Cescon DW, Im SA, et al
    Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.
    N Engl J Med. 2022;387:217-226.
    PubMed     Abstract available


  50. THORNHILL JP, Barkati S, Walmsley S, Rockstroh J, et al
    Monkeypox Virus Infection in Humans across 16 Countries - April-June 2022.
    N Engl J Med. 2022 Jul 21. doi: 10.1056/NEJMoa2207323.
    PubMed     Abstract available


  51. HUNG WK, Chung WH
    Drug Reaction with Eosinophilia and Systemic Symptoms.
    N Engl J Med. 2022;387:167.
    PubMed    


  52. HURVITZ SA
    DESTINY-Changing Results for Advanced Breast Cancer.
    N Engl J Med. 2022;387:75-76.
    PubMed    


    June 2022
  53. JATOI I, Sung H, Jemal A
    The Emergence of the Racial Disparity in U.S. Breast-Cancer Mortality.
    N Engl J Med. 2022;386:2349-2352.
    PubMed    


  54. ROKHZAN R, Meier K
    Targeted Therapy in Melanoma.
    N Engl J Med. 2022;386:e66.
    PubMed    


  55. CORTES J, Im SA, Cathcart J
    Trastuzumab Deruxtecan for Breast Cancer. Reply.
    N Engl J Med. 2022;386:2347.
    PubMed    


  56. ZHENG F, Du F, Yuan P
    Trastuzumab Deruxtecan for Breast Cancer.
    N Engl J Med. 2022;386:2346-2347.
    PubMed    


  57. BASGOZ N, Brown CM, Smole SC, Madoff LC, et al
    Case 24-2022: A 31-Year-Old Man with Perianal and Penile Ulcers, Rectal Pain, and Rash.
    N Engl J Med. 2022 Jun 15. doi: 10.1056/NEJMcpc2201244.
    PubMed    


  58. MODI S, Jacot W, Yamashita T, Sohn J, et al
    Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
    N Engl J Med. 2022 Jun 5. doi: 10.1056/NEJMoa2203690.
    PubMed     Abstract available


    May 2022
  59. FAJGENBAUM DC, Goiffon RJ, Soumerai JD, Harris CK, et al
    Case 16-2022: A 55-Year-Old Man with Fevers, Night Sweats, and a Mediastinal Mass.
    N Engl J Med. 2022;386:2036-2048.
    PubMed    


  60. TAWBI HA, Hodi FS, Long GV
    Nivolumab with or without Relatlimab in Untreated Advanced Melanoma. Reply.
    N Engl J Med. 2022;386:1860-1861.
    PubMed    


  61. HINDIE E
    Nivolumab with or without Relatlimab in Untreated Advanced Melanoma.
    N Engl J Med. 2022;386:1860.
    PubMed    


  62. ALHATEM A, Smith KC
    Primary Cutaneous Blastomycosis.
    N Engl J Med. 2022;386:e49.
    PubMed    


  63. SCHMID P, Cortes J, Dent R
    Pembrolizumab in Early Triple-Negative Breast Cancer. Reply.
    N Engl J Med. 2022;386:1771-1772.
    PubMed    


  64. GANGULY S, Gogia A
    Pembrolizumab in Early Triple-Negative Breast Cancer.
    N Engl J Med. 2022;386:1771.
    PubMed    


  65. MESSENGER A, Harries M
    Baricitinib in Alopecia Areata.
    N Engl J Med. 2022;386:1751-1752.
    PubMed    


  66. KING B, Ohyama M, Kwon O, Zlotogorski A, et al
    Two Phase 3 Trials of Baricitinib for Alopecia Areata.
    N Engl J Med. 2022;386:1687-1699.
    PubMed     Abstract available


    April 2022
  67. BRYANT-STEPHENS T
    Breaking the Skin Color Barriers for Asthma Medications - It's Not Black, Brown, or White.
    N Engl J Med. 2022;386:1574-1575.
    PubMed    


    March 2022
  68. CORTES J, Kim SB, Chung WP, Im SA, et al
    Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
    N Engl J Med. 2022;386:1143-1154.
    PubMed     Abstract available


  69. ZHANG P, Chen L
    Melanoma of the Palpebral Conjunctiva and Eyelid.
    N Engl J Med. 2022 Mar 19. doi: 10.1056/NEJMicm2115699.
    PubMed    


  70. LONGHURST HJ, Ameratunga R
    An Antisense Oligonucleotide for Hereditary Angioedema.
    N Engl J Med. 2022;386:1083-1085.
    PubMed    


  71. BANERJI A, Phadke NA, Gottumukkala R, Sharma R, et al
    Case 8-2022: A 54-Year-Old Woman with Episodes of Swelling.
    N Engl J Med. 2022;386:1071-1079.
    PubMed    


  72. LUEKING R, Lazarte S
    Malignant Syphilis.
    N Engl J Med. 2022;386:e26.
    PubMed    


  73. FIJEN LM, Riedl MA, Bordone L, Bernstein JA, et al
    Inhibition of Prekallikrein for Hereditary Angioedema.
    N Engl J Med. 2022;386:1026-1033.
    PubMed     Abstract available


  74. ALAGESAN M, Chidambaram Y
    Pellagra.
    N Engl J Med. 2022;386:e24.
    PubMed    


  75. HORTOBAGYI GN, Stemmer SM, Burris HA, Yap YS, et al
    Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.
    N Engl J Med. 2022;386:942-950.
    PubMed     Abstract available


    February 2022
  76. LEUNG TH, Cotsarelis G
    Cellular Memories - More Than Skin Deep.
    N Engl J Med. 2022;386:793-795.
    PubMed    


  77. SILVERMAN RF, Shinder R
    Molluscum Contagiosum.
    N Engl J Med. 2022;386:582.
    PubMed    


  78. SCHMID P, Cortes J, Dent R, Pusztai L, et al
    Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
    N Engl J Med. 2022;386:556-567.
    PubMed     Abstract available


  79. YOKOYAMA T
    Chronic Generalized Pruritus.
    N Engl J Med. 2022;386:e12.
    PubMed    


  80. BRAGA NETO MB, Badley AD, Parikh SA, Graham RP, et al
    Calm before the Storm.
    N Engl J Med. 2022;386:479-485.
    PubMed    


    January 2022
  81. GRAYSON PC, Perugino CA, Dinculescu VV, Ferry JA, et al
    Case 2-2022: A 70-Year-Old Man with a Recurrent Left Pleural Effusion.
    N Engl J Med. 2022;386:274-283.
    PubMed    


  82. MAHARAJH S, Teelucksingh S
    Hyperpigmentation in Vitamin B12 Deficiency.
    N Engl J Med. 2022;386:172.
    PubMed    


  83. FRAMPTON AE, Sivakumar S
    A New Combination Immunotherapy in Advanced Melanoma.
    N Engl J Med. 2022;386:91-92.
    PubMed    


  84. TAWBI HA, Schadendorf D, Lipson EJ, Ascierto PA, et al
    Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.
    N Engl J Med. 2022;386:24-34.
    PubMed     Abstract available


  85. JOHN LN, Beiras CG, Houinei W, Medappa M, et al
    Trial of Three Rounds of Mass Azithromycin Administration for Yaws Eradication.
    N Engl J Med. 2022;386:47-56.
    PubMed     Abstract available


    December 2021
  86. SHARMA V, Kumar A
    Carcinoma en Cuirasse.
    N Engl J Med. 2021;385:2562.
    PubMed    


  87. BACHELEZ H, Choon SE, Marrakchi S, Burden AD, et al
    Trial of Spesolimab for Generalized Pustular Psoriasis.
    N Engl J Med. 2021;385:2431-2440.
    PubMed     Abstract available


  88. KATAYAMA S, Ota M
    Minocycline-Induced Hyperpigmentation.
    N Engl J Med. 2021;385:2463.
    PubMed    


  89. KALINSKY K, Barlow WE, Gralow JR, Meric-Bernstam F, et al
    21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.
    N Engl J Med. 2021;385:2336-2347.
    PubMed     Abstract available


  90. WILLETT LL, Bromberg GK, Chung R, Leaf RK, et al
    Case 38-2021: A 76-Year-Old Woman with Abdominal Pain, Weight Loss, and Memory Impairment.
    N Engl J Med. 2021;385:2378-2388.
    PubMed    


  91. DILLY B, Bomahou C
    Tongue Necrosis in Giant-Cell Arteritis.
    N Engl J Med. 2021;385:2377.
    PubMed    


  92. MCKINLEY TD, Maroon M
    Linear Darier's Disease.
    N Engl J Med. 2021;385:e91.
    PubMed    


  93. BIEBER T
    AhR Modulating Agent for the Topical Therapy of Plaque Psoriasis.
    N Engl J Med. 2021;385:2295-2296.
    PubMed    


  94. LEBWOHL MG, Stein Gold L, Strober B, Papp KA, et al
    Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis.
    N Engl J Med. 2021;385:2219-2229.
    PubMed     Abstract available


  95. KUECKELHAUS M, Rothoeft T, De Rosa L, Yeni B, et al
    Transgenic Epidermal Cultures for Junctional Epidermolysis Bullosa - 5-Year Outcomes.
    N Engl J Med. 2021;385:2264-2270.
    PubMed     Abstract available


  96. WALLACE ZS, Rodriguez K, Dau J, Bloch DB, et al
    Case 37-2021: A 60-Year-Old Man with Fevers, Fatigue, Arthralgias, a Mouth Ulcer, and a Rash.
    N Engl J Med. 2021;385:2282-2293.
    PubMed    


  97. KALLESH A, Kumar VS
    Congenital Langerhans-Cell Histiocytosis.
    N Engl J Med. 2021;385:e86.
    PubMed    


    November 2021
  98. WINSTON LG, Winkler ML, Kheterpal A, Villalba JA, et al
    Case 36-2021: A 22-Year-Old Man with Pain and Erythema of the Left Hand.
    N Engl J Med. 2021;385:2078-2086.
    PubMed    


  99. WANG T, Chen JQ
    Tinea Capitis Due to Microsporum canis.
    N Engl J Med. 2021;385:2077.
    PubMed    


  100. VARONI EM, Decani S
    Gingival Melanoma.
    N Engl J Med. 2021;385:e73.
    PubMed    


  101. DIETZ BW, Winston LG, Koehler JE, Margaretten M, et al
    Copycat.
    N Engl J Med. 2021;385:1797-1802.
    PubMed    


    October 2021
  102. ASKENASE PW
    Rare Skin Reactions after mRNA Vaccination, Similar to Jones-Mote Basophil Responses.
    N Engl J Med. 2021;385:1720-1721.
    PubMed    


  103. AKINTILO L, Femia A
    Disseminated Cryptococcosis.
    N Engl J Med. 2021;385:1699.
    PubMed    


  104. RAMIREZ-LLUCH M, Hernandez-Martin A
    Pearly Penile Papules.
    N Engl J Med. 2021;385:1420.
    PubMed    


  105. TUTT ANJ, Garber JE, Geyer CE Jr
    Adjuvant Olaparib in BRCA-Mutated Breast Cancer. Reply.
    N Engl J Med. 2021;385:1440.
    PubMed    


  106. HOSHI A, Bando H, Sekine I
    Adjuvant Olaparib in BRCA-Mutated Breast Cancer.
    N Engl J Med. 2021;385:1439-1440.
    PubMed    


  107. NOZAWA K, Yoshimura A, Iwata H
    Adjuvant Olaparib in BRCA-Mutated Breast Cancer.
    N Engl J Med. 2021;385:1439.
    PubMed    


    September 2021
  108. LINDSAY ME, Dudzinski DM, Yoon BC, Jaff MR, et al
    Case 30-2021: A 47-Year-Old Man with Recurrent Unilateral Head and Neck Pain.
    N Engl J Med. 2021;385:1317-1325.
    PubMed    


  109. BARRY D, Schmieder A
    Leukemia Cutis.
    N Engl J Med. 2021;385:1316.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Dermatology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: